{{Rsnum
|rsid=11023197
|Gene=RRAS2
|Chromosome=11
|position=14359452
|Orientation=plus
|GMAF=0.303
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=RRAS2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 15.0 | 41.6 | 43.4
| HCB | 13.9 | 45.3 | 40.9
| JPT | 15.9 | 51.3 | 32.7
| YRI | 1.4 | 19.7 | 78.9
| ASW | 5.3 | 31.6 | 63.2
| CHB | 13.9 | 45.3 | 40.9
| CHD | 14.7 | 47.7 | 37.6
| GIH | 13.0 | 45.0 | 42.0
| LWK | 0.0 | 7.3 | 92.7
| MEX | 6.9 | 48.3 | 44.8
| MKK | 2.6 | 23.1 | 74.4
| TSI | 18.6 | 38.2 | 43.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11023197
|Name_s=TC21 (RRAS2) -582C>T, RRAS2:(-582)C>T
|Gene_s=RRAS2
|Feature=
|Evidence=PubMed ID:19047159
|Annotation=In a study of tamoxifen treated breat cancer patients, carrying the T variant of RRAS2:(-582)C>T was associated with a higher frequency of relapse.
|Drugs=tamoxifen
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165107300
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11023197
|overall_frequency_n=43
|overall_frequency_d=128
|overall_frequency=0.335938
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=36
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}